CBST will buy the EU rights of tedizolid for 100 million, paying a 10% percent royalty to TSRX on future sales. Additionally, CBST will pay for 25% of develpment costs of tedizolid in HABP/VABP trials.
The launch of tedizolid will coincide with CBST launch of ceftolanzane/tazobactam in the EU, giving CBST the premier gram positve and gram negative antibiotics in the EU. CBST is currently building their European sales force to accomodate the launch of both drugs.
Just a WAG, but get ready to read an announcement like this soon. CBST aggressively pursuring acquistions and right to products. This one make sense for them in the EU
Pfizer buys Trius lock stock and barrel and uses their clout with their billion dollar drug, Zyvox, to insert "Trivox" into the market before losing the revenue to generic competition. Pfizer is in a unique position to guarantee the success of the "new and improved" oxazolidinone and reap the revenue rewards for years to come by keeping the price of Zyvox high and offering the new and better drug to hospital formularies for the same cost. It would be a no-brainer for formularies to make the change and once the providers get used to the benefits, it would be difficult to get them to morph back to generic linezolid in a few years.
That could very well happen. I love your Trivox name! When you are done with the ER, you may have a future in marketing!!
PFE certainly has deep enough pockets to do whatever it likes. And their hospital anti-infective sales force won't have much to do after Zyvox goes generic. Tygacil has't done much. Eraxis is all about contracting. Makes sense for them if they want to keep a hospital presence.